These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1349173)

  • 1. Macromolecular assemblage in the design of a synthetic AIDS vaccine.
    Defoort JP; Nardelli B; Huang W; Ho DD; Tam JP
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3879-83. PubMed ID: 1349173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.
    Lapham C; Golding B; Inman J; Blackburn R; Manischewitz J; Highet P; Golding H
    J Virol; 1996 May; 70(5):3084-92. PubMed ID: 8627787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rational design of synthetic peptide vaccine with a built-in adjuvant. A modular approach for unambiguity.
    Defoort JP; Nardelli B; Huang W; Tam JP
    Int J Pept Protein Res; 1992; 40(3-4):214-21. PubMed ID: 1478779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group.
    Corey L; McElrath MJ; Weinhold K; Matthews T; Stablein D; Graham B; Keefer M; Schwartz D; Gorse G
    J Infect Dis; 1998 Feb; 177(2):301-9. PubMed ID: 9466515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological reactivity of a human immunodeficiency virus type I derived peptide representing a consensus sequence of the GP120 major neutralizing region V3.
    Wagner R; Modrow S; Böltz T; Fliessbach H; Niedrig M; von Brunn A; Wolf H
    Arch Virol; 1992; 127(1-4):139-52. PubMed ID: 1456889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric influenza virus induces neutralizing antibodies and cytotoxic T cells against human immunodeficiency virus type 1.
    Li S; Polonis V; Isobe H; Zaghouani H; Guinea R; Moran T; Bona C; Palese P
    J Virol; 1993 Nov; 67(11):6659-66. PubMed ID: 7692083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
    Hart MK; Palker TJ; Matthews TJ; Langlois AJ; Lerche NW; Martin ME; Scearce RM; McDanal C; Bolognesi DP; Haynes BF
    J Immunol; 1990 Oct; 145(8):2677-85. PubMed ID: 1698859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative.
    Bartlett JA; Wasserman SS; Hicks CB; Dodge RT; Weinhold KJ; Tacket CO; Ketter N; Wittek AE; Palker TJ; Haynes BF
    AIDS; 1998 Jul; 12(11):1291-300. PubMed ID: 9708408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope.
    Letvin NL; Robinson S; Rohne D; Axthelm MK; Fanton JW; Bilska M; Palker TJ; Liao HX; Haynes BF; Montefiori DC
    J Virol; 2001 May; 75(9):4165-75. PubMed ID: 11287566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
    Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
    J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brucella abortus conjugated with a gp120 or V3 loop peptide derived from human immunodeficiency virus (HIV) type 1 induces neutralizing anti-HIV antibodies, and the V3-B. abortus conjugate is effective even after CD4+ T-cell depletion.
    Golding B; Inman J; Highet P; Blackburn R; Manischewitz J; Blyveis N; Angus RD; Golding H
    J Virol; 1995 Jun; 69(6):3299-307. PubMed ID: 7745677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 proteins in infected cells determine the presentation of viral peptides by HLA class I and class II molecules and the nature of the cellular and humoral antiviral immune responses--a review.
    Becker Y
    Virus Genes; 1994 Jul; 8(3):249-70. PubMed ID: 7975271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    J Virol; 1994 May; 68(5):3145-53. PubMed ID: 7908700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Barnett SW; Rajasekar S; Legg H; Doe B; Fuller DH; Haynes JR; Walker CM; Steimer KS
    Vaccine; 1997 Jun; 15(8):869-73. PubMed ID: 9234536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.